Preclinical data are encouraging but early — the Phase 1 trial has not yet initiated. Monitor for trial start confirmation and any partnership or financing updates that could extend the cash runway through the data readout in H2 2027.
Price Chart
Executive Summary
Jade Biosciences announced preclinical data for JADE301, an anti-IFN-β monoclonal antibody for dermatomyositis, showing superior potency and pharmacokinetics vs a dazukibart comparator. The company expects to initiate a Phase 1 trial in Q4 2026 with interim data in H2 2027. This is an early-stage pipeline update with no financial data or near-term revenue catalyst.
Key Facts
- JADE301 is a fully human IgG1 monoclonal antibody targeting IFN-β for dermatomyositis (DM)
- Preclinical data showed 2.5-fold higher binding affinity (KD 11.3 pM) vs dazukibart comparator
- 8-fold more potent suppression of MX-1 in human dermal fibroblasts vs comparator (IC50 11 pM)
- ~30-day half-life in NHPs (IV), ~3-fold longer than comparator; predicted human SC bioavailability 73-75% vs 43-44% for dazukibart
- GLP toxicology in NHPs well tolerated at all doses (0, 50, 100, 200 mg/kg SC every 2 weeks)
- Phase 1 placebo-controlled SAD trial in 24 healthy volunteers expected to start Q4 2026; interim data H2 2027
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech with no near-term revenue impact
Risk Factors
- Preclinical potency and PK may not translate to clinical efficacy in DM patients
- Phase 1 trial could be delayed or fail to demonstrate adequate safety/tolerability
- No disclosed cash position or financing plan to support development through Phase 1 completion
- Dermatomyositis is a rare disease with limited commercial precedent for novel biologics
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-408287 |
| Document: 0001193125-26-408287-index-headers.html | 0001193125-26-408287 |
| Document: 0001193125-26-408287-index.html | 0001193125-26-408287 |
| Document: 0001193125-26-408287.txt | 0001193125-26-408287 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.50 (+3.20%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.50 (−33.27%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.50 (+3.20%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.50 (+14.40%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.50 (+18.26%) |
Jun 1, 2026 21w ago | 8-K | $18.59 $16.94 | ▼ −8.88% | ▼ −6.13% | $14.50 (−22.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers